单纯TH方案及其联合贝伐单抗治疗Her-2阳性转移性乳腺癌的疗效观察

Observation on the Curative Effect of TH Regimen Alone and Combined with Bevacizumab in the Treatment of Her-2 Positive Metastatic Breast Cancer

目的探讨单纯TH方案及其联合贝伐单抗治疗Her-2阳性转移性乳腺癌的效果。方法选取治疗的Her-2阳性转移性乳腺癌患者80例作为研究对象,采用数字随机对照表将患者分为对照组和观察组,对照组予以单独TH方案治疗,观察组在对照组基础上予以贝伐单抗治疗,观察两组临床疗效及化疗毒副反应,记录两组中位疾病进展时间(TTP)和中位无进展生存期(PFS)。结果观察组治疗总有效率为52.5%较对照组22.5%高,差异具有统计学意义(P<0.05);观察组TTP和PFS分别为(15.67±2.97)月、(21.65±1.58)月均较对照组长,差异具有统计学意义(P<0.05)。结论单纯TH方案联合贝伐单抗治疗Her-2阳性转移性乳腺癌,能够提高临床疗效,延长患者PFS时间,且不会增加不良用药反应。

Objective To explore the effect of TH regimen alone and combined with bevacizumab in the treatment of Her- 2 positive metastatic breast cancer. Methods 80 cases of patients with Her- 2 positive metastatic breast cancer admitted into the hospital for treatment were selected as the research object and were divided into the control group and the observation group by the random number table. The control group were treated with TH regimen alone while the observation group were treated with bevacizumab on the basis of the treatment of the control group. The clinical curative effect and side effects of chemotherapy in the two groups were observed and the median time to progressive disease（ TTP） and median progression free survival（ PFS） were recorded. Results In the observation group,the total effective rate was 52. 5% which was higher than 22. 5% in the control group and the difference was of statistical significance（ P〈0. 05）; TTP and PFS of the observation group respectively was（ 15. 67 ± 2. 97） months and（ 21. 65 ± 1. 58） monthly which was longer thanthat of the control group and the difference was of statistical significance（ P〈0. 05）. Conclusions TH regimen alone combined with bevacizumab in the treatment of Her- 2 positive metastatic breast cancer can improve the clinical efficacy,prolong the time of PFS,and does not increase the adverse drug reaction.